Latest Fentanyl Stories

On April 19th, 2012 the US FDA issued a safety alert to warn patients, caregivers and health care professionals about the dangers of accidental exposure to and improper storage and disposal of the Fentanyl patch because young children have died or become seriously ill from accidental exposure to the patch. Fentanyl is the generic name for an extremely potent synthetic narcotic drug often used for cancer patients. On January 3rd, 2012, a California man, Jose Campuzano filed a lawsuit (case...

RALEIGH, N.C., May 9, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch Healthcare Conference at Encore at the Wynn Hotel, Las Vegas, Nevada. The presentation is scheduled for Thursday, May 17, 2012 at 11:20 A.M. Pacific Time (2:20 P.M. Eastern Time). (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) Dr. Sirgo...

CUPERTINO, Calif., May 3, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2012. Excluding the accelerated recognition of deferred revenue described below, DURECT's reported revenues would have been $5.8 million for the three months ended March 31, 2012 (as compared to $8.6 million for the same period in 2011) and reported net loss would have been $4.6 million for the three months ended March 31, 2012 (as...

OTTAWA, April 17, 2012 /PRNewswire/ - Health Canada today released the April 2012 issue of the Canadian Adverse Reaction Newsletter (CARN). This edition contains an article on a suspected association between the long-term use of the antibiotic minocycline for the treatment of acne in adolescents and two serious autoimmune disorders: drug-induced lupus erythematosus (a type of lupus), and autoimmune hepatitis (liver inflammation). It also includes an article on the painkiller...

RALEIGH, N.C., April 17, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that the U.S. Patent and Trademark Office (USPTO) has formally awarded BDSI's patent No. 13/184306, "Transmucosal Delivery Devices with Enhanced Uptake," which extends the patent protection for BDSI's BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven years to 2027. The USPTO had issued a Notice of Allowance to BDSI for...

RALEIGH, N.C., April 16, 2012 /PRNewswire/-- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center, New York City. The presentation is scheduled for Friday, April 20, 2012 at 3:00 P.M. Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) Dr. Sirgo...

As published on March 27th, 2012 in the Pharmaceutical Business Review, Insys Therapeutics launched Subsys (Fentanyl sublingual spray) for the management of persistent cancer pain. Fentanyl is a potent synthetic narcotic analgesic used to treat breakthrough cancer pain and is commonly used in pre-procedures as a pain reliever as well as an anesthetic. On September 2nd 2011, the widower of a New York woman, Steven Shemelia filed a lawsuit (case no. 2:2011cv05559) at the Philadelphia Court...

Does not have the side effects of fentanyl and other narcotics Patients who have undergone sinus surgery can safely take an alternative pain medication that does not cause the side effects of narcotics such as fentanyl and Vicodin, a Loyola University Health System study has found. The alternative medication is ketorolac (brand name, Toradol). It is in the same class of nonsteroidal anti-inflammatory drugs as Advil and Aleve. Ketorolac does not cause the side effects that narcotic drugs...

On March 12th 2012, BioDelivery Sciences International, Inc. announced that the U.S. re-launch of Onsolis (Fentanyl buccal soluble film) is being postponed until the product formulation can be modified to address two appearance issues raised by the U.S. Food and Drug Administration (FDA). Fentanyl (brand names Duragesic, Onsolis and others) is a potent synthetic narcotic analgesic used to treat breakthrough cancer pain and is commonly used in pre-procedures as a pain reliever as well as an...

RALEIGH, N.C., March 19, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2011, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of the Company's achievements and an update on business operations and upcoming milestones for 2012. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) In 2011, BDSI...